Usman Iqbal MD,MPH,MBA Email & Phone Number

Usman Iqbal MD,MPH,MBA is a Advisory Board Member at Humanity Talent Network based in Greater Boston, United States, North America. Recognized and Included in Marquis Who's Who (in 2023) for expertise in Biopharmaceuticals, Medical Economics, and Public health A strategic steward, end to end Implementation Specialist and Gap Analyses Expert with o Over 15 years of end-to-end experience spanning R&D, Global Med Affairs, HEOR, Value & Access across both large and small cap biopharmaceutical o Global/US Experience, Thought Leadership and Executional Excellence in 1) Clinical Development Strategy & cross functional program management 2) Launch Planning 3) End-Point Strategy & Trial design Optimizations 4) Integrated Medical Affairs 5) Real World Evidence Generation, Regulatory Grade BIG DATA Platforms Development 6) PROs & COAs 7) Pharmacovigilance, benefit risk assessment and RMP development o Multidimensional end to end expertise entailing value based drug development, Integrated Clinical-Medical Affairs Strategy, BIG DATA stewardship, Label Negotiations & NDAs, HTA Access and Product Differentiation across multiple therapeutic areas including Bone Health, Oncology, Neuroscience, Rare Disease, Musculoskeletal/Inflammatory, Gene Therapies o Thought-leadership and Demonstrated experience in medical value based 3P stakeholder engagement (patients, payers, physicians), medical affairs functional & capability build up, leading transversal platforms and translating patient centricity into a strategic management function o RWE/BIG DATA Expertise: Customized Regulatory Grade RWE Data Platform Development, Stewardship for Fit for purpose enterprise level RWE ecosystems, product strategies and end to end cross functional integration Advanced analytical and AI interface engines. Scientific Advisership & Thought Leadership on RWE collaborations and advancements, Due Diligences for Investment firms; Facilitated 6 RWE M&A and 1 IPO o Strategic product development and medical positioning of companion diagnostics & biomarkers. Dedicated Thought Leadership in developing evidentiary guidelines and strategic pathways to demonstrate clinical validity, utility and preferred reimbursement of biologics and molecular diagnostics in Adult Oncology, rare diseases and neuroscience o Fractional Services to CMOs and R&D teams on End-to End Development strategy, Protocols & Trial Design Optimizations, Pharmacovigilance, Regulatory Grade RWE BIG DATA Platforms, Competitive differentiation, TPP risk mitigation, proactive planning on integrated phase 3b/4 evidence generation with an "end in mind" approach • Interim/Fractional CMO/COO offerings to small cap biopharma and digital health companies